|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
|
Oct 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria
|
Dec 2019
|
Leukemia & Lymphoma
|
aplastic anemia
|
|
Eat and be healthy: nutritional status in myelodysplastic syndromes
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?
|
Jun 2023
|
Leukemia & Lymphoma
|
aplastic anemia
|
|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
